Y-mAbs Therapeutics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $20.80M Beat $20.35M Estimate
Portfolio Pulse from Benzinga Newsdesk
Y-mAbs Therapeutics reported Q2 earnings per share (EPS) of $(0.14), beating the analyst consensus estimate of $(0.24) by 41.67%. The company also reported quarterly sales of $20.80 million, surpassing the analyst consensus estimate of $20.35 million by 2.21%. Both EPS and sales figures represent significant increases over the same period last year.
August 10, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Y-mAbs Therapeutics reported better than expected Q2 earnings and sales, which could positively impact its stock price in the short term.
Y-mAbs Therapeutics reported Q2 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100